We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI Model for Brain Tumor Classification Advances Neuropathology

By LabMedica International staff writers
Posted on 28 Dec 2023

Diffuse gliomas, which comprise a large portion of malignant brain tumors in adults, include various types such as astrocytoma, oligodendroglioma, and glioblastoma. Diagnosing these types of gliomas traditionally relies on an analysis that integrates histological characteristics with molecular details, a method that presents significant complexities when attempting to develop a comprehensive diagnostic model from whole-slide images (WSIs). The immense gigapixel resolution of WSIs renders the use of standard convolutional neural networks for analysis impractical. To address this challenge, researchers have now introduced a novel integrated diagnostic model that can automatically classify adult-type diffuse gliomas directly from unannotated standard whole-slide pathological images, eliminating the need for additional molecular testing.

Researchers from the Chinese Academy of Sciences (CAS, Beijing, China) have devised this deep learning model capable of parsing WSIs and categorizing gliomas without the need for detailed manual annotations. This model adheres to the strict classification guidelines outlined in the 2021 fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System. The model underwent training and validation across a diverse dataset comprising 2,624 patient cases collected from three different hospitals.


Image: Ten examples of classification results on the external testing sets (Photo courtesy of Nature Communications, 2023)
Image: Ten examples of classification results on the external testing sets (Photo courtesy of Nature Communications, 2023)

The model's effectiveness was evaluated based on its classification accuracy, sensitivity to various glioma types and grades, and its capability to differentiate between genotypes that exhibit similar histological characteristics. The outcomes of the experiments indicate that the model demonstrates robust performance, with all areas under the receiver operator curve exceeding 0.90. This performance was noted in its ability to classify major tumor types, identify tumor grades within each type, and, notably, distinguish between tumor genotypes that share the same histological features.

"Our integrated diagnosis model has the potential to be used in clinical scenarios for automated and unbiased classification of adult-type diffuse gliomas," said CAS Prof. Li Zhicheng who led the research team. "The future research will focus on improving this model to have multi-center, multi-racial datasets."

Related Links:
Chinese Academy of Sciences


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Latest Pathology News

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization